Analysts Set Guardant Health, Inc. (NASDAQ:GH) PT at $106.86

Guardant Health, Inc. (NASDAQ:GH) has earned a consensus recommendation of “Moderate Buy” from the twenty-three analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twenty-one have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $106.8571.

GH has been the subject of a number of analyst reports. Evercore set a $105.00 price objective on Guardant Health and gave the stock an “in-line” rating in a research report on Monday, January 5th. Leerink Partners increased their target price on shares of Guardant Health from $115.00 to $155.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. UBS Group restated a “buy” rating and set a $175.00 price target on shares of Guardant Health in a report on Friday, January 30th. Canaccord Genuity Group upped their price objective on shares of Guardant Health from $100.00 to $125.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Finally, Piper Sandler increased their price objective on shares of Guardant Health from $60.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd.

Guardant Health Stock Up 2.0%

NASDAQ GH opened at $104.85 on Friday. The company has a market capitalization of $13.22 billion, a price-to-earnings ratio of -32.66 and a beta of 1.63. Guardant Health has a twelve month low of $34.88 and a twelve month high of $120.74. The stock has a fifty day simple moving average of $106.39 and a 200 day simple moving average of $84.77.

Insider Activity

In other news, CTO Darya Chudova sold 5,451 shares of the business’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $104.04, for a total value of $567,122.04. Following the transaction, the chief technology officer directly owned 7,012 shares of the company’s stock, valued at $729,528.48. The trade was a 43.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Helmy Eltoukhy sold 90,565 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $103.82, for a total value of $9,402,458.30. Following the sale, the chief executive officer directly owned 2,047,143 shares of the company’s stock, valued at $212,534,386.26. This represents a 4.24% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 434,627 shares of company stock worth $45,592,052. 6.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. V Square Quantitative Management LLC bought a new stake in shares of Guardant Health during the fourth quarter valued at approximately $27,000. Chesapeake Asset Management LLC acquired a new stake in Guardant Health in the 4th quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Guardant Health in the 4th quarter valued at $31,000. IFP Advisors Inc increased its stake in Guardant Health by 120.1% during the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after purchasing an additional 334 shares in the last quarter. Finally, Elyxium Wealth LLC acquired a new position in Guardant Health during the fourth quarter worth $35,000. 92.60% of the stock is owned by institutional investors and hedge funds.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.